Supplementary Figure S5 from Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition

Mae, Hirokazu; Outani, Hidetatsu; Imura, Yoshinori; Chijimatsu, Ryota; Inoue, Akitomo; Kotani, Yuki; Yasuda, Naohiro; Nakai, Sho; Nakai, Takaaki; Takenaka, Satoshi; Okada, Seiji

doi:10.1158/2767-9764.23618559.v1

- No file added yet -

Supplementary Figure S5 from Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition

journal contribution

posted on 2023-07-03, 14:20 authored by Hirokazu Mae, Hidetatsu Outani, Yoshinori Imura, Ryota Chijimatsu, Akitomo Inoue, Yuki Kotani, Naohiro Yasuda, Sho Nakai, Takaaki Nakai, Satoshi Takenaka, Seiji Okada

Fig. S5 A combination of vorinostat and mivebresib is effective for CCS

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)

Osaka Medical Research Foundation for Intractable Diseases

History

ARTICLE ABSTRACT

This study reveals the epigenetic and transcriptional suppression mechanism of the fusion oncogene EWSR1::ATF1 in clear cell sarcoma by histone deacetylase inhibitor treatment as well as identifying SOX10 as a transcription factor that regulates EWSR1::ATF1 expression.

Usage metrics

Keywords

Sarcomas Soft-tissue sarcoma Drug Targets Oncoprotein & tumor suppressor drug targets Oncogenes & Tumor Suppressors Oncogenes Gene Regulation Small Molecule Agents HDAC & methyltransferase inhibitors Epigenetics

Licence

CC BY

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplementary Figure S5 from Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)

Osaka Medical Research Foundation for Intractable Diseases

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports